Evaluation of the effect of nanoliposomal amphotericin B in the treatment of patients with resistant dermatophytosis

Determining the efficacy of topical nanoliposomal amphotericin B in individuals with treatment-resistant dermatophytosis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240711062393N2

Enrollment

Registered

2025-06-07

Start date

2025-07-23

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatophytosis is an inflammatory skin infection caused by dermatophyte fungi including Trichophyton, Microsporum, Epidermophyton, Lophophyton, Nannizzia, Parathion, and Arthroderma.. Dermatophytosis

Interventions

Intervention 1: Group 1: Patients with treatment-resistant dermatophytosis (non-onychomycosis) who will receive nanoliposomal amphotericin B. Sina Ampholish 0.4% ointment is used twice a day for 4 wee

Eligibility

Sex/Gender

All

Age

20 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with treatment-resistant Dermatophytosis

Exclusion criteria

Exclusion criteria: Neonates and children range from 0 to 19 years Pregnant mothers

Design outcomes

Primary

Measure	Time frame
Percentage of Individuals with treatment-resistant dermatophytosis. Timepoint: Patients are evaluated at the beginning of the study. Method of measurement: Assessing lesion size, itch, and inflammation based on observation.;Complete clinical response. Timepoint: Patients are evaluated after 2 and 4 weeks of treatment. Method of measurement: Assessing improvement of lesion size, itch, and inflammation based on the questionnaire scoring.;No response to treatment. Timepoint: Patients are evaluated after 2 and 4 weeks of treatment. Method of measurement: Assessing improvement of lesion size, itch, and inflammation based on the questionnaire scoring.;Independent variable-Nano-Liposomal Amphotercin b drug. Timepoint: Patients are evaluated after 2 and 4 weeks of treatment. Method of measurement: Patient grouping (drug-receiving group vs. control).;Dependent variable-effectiveness. Timepoint: Patients are evaluated after 2 and 4 weeks of treatment. Method of measurement: Clinical outcomes.	—

Measure

Time frame

Percentage of Individuals with treatment-resistant dermatophytosis. Timepoint: Patients are evaluated at the beginning of the study. Method of measurement: Assessing lesion size, itch, and inflammation based on observation.;Complete clinical response. Timepoint: Patients are evaluated after 2 and 4 weeks of treatment. Method of measurement: Assessing improvement of lesion size, itch, and inflammation based on the questionnaire scoring.;No response to treatment. Timepoint: Patients are evaluated after 2 and 4 weeks of treatment. Method of measurement: Assessing improvement of lesion size, itch, and inflammation based on the questionnaire scoring.;Independent variable-Nano-Liposomal Amphotercin b drug. Timepoint: Patients are evaluated after 2 and 4 weeks of treatment. Method of measurement: Patient grouping (drug-receiving group vs. control).;Dependent variable-effectiveness. Timepoint: Patients are evaluated after 2 and 4 weeks of treatment. Method of measurement: Clinical outcomes.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Abastabar

Mazandaran University of Medical Sciences

marieh.rajabalian@yahoo.com+98 11 3304 4000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026